Base to Base biotech podcast 66: The future of clinical trials and breakthroughs in molecular testing

This week, we have a conversation with Jeff Fischer, president of Longhorn Vaccines & Diagnostics, and with Hannah Amies, founder and CEO of Luvida.Times:03:03 Longhorn Vaccines and Diagnostics25:03 LuvidaLonghorn Vaccines & Diagnostics on breakthroughs in molecular testingMaryland-based Longhorn Vaccines and Diagnostics is a IND-enabling stage biopharmaceutical company developing vaccines, monoclonal antibodies, and diagnostics targeting pathogens.The company focuses on innovative approaches to addressing major public health challenges including antimicrobial resistance, sepsis, and inflammatory disease.Started in 2006 with the invention of inactivating molecular transport media for collection of respiratory samples and the stabilization of nucleic acid at ambient temperature for weeks to months, Longhorn created the product category and the predicate device at the U. S. Food and Drug Administration.Luvida – solving clinical trial bottlenecksLuvida is an AI data platform that helps pharma, biotech, and CRO teams design clinical trials.Most trials don’t fail because of bad science. The biology is well understood, but the factors that drive recruitment, adherence, and drop-out aren’t used at scale. Luvida solves this with proprietary Electronic Life Records, a data layer that captures how patients live, and uses explainable AI to surface trial risk before a single patient is enrolled. The result is faster, data-driven protocols, with fewer costly amendments, and trials that complete faster. Ultimately, this means medicines that reach patients sooner.To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]